Rules-Based Medicine (RBM) is a biotechnology company based in the United States that specializes in the development and commercialization of multiplex immunoassay testing services. The company was founded in 2002 by Craig Benson and Dr. Ron Rodland, and since its establishment, it has gained recognition as a leader in the field of biomarker testing and analysis.

RBM’s headquarters is located in Austin, Texas, where it operates various laboratories and manufacturing facilities. The company also maintains a global presence through its subsidiaries and partnerships. Notably, in 2012, RBM was acquired by Myriad Genetics, a leading molecular diagnostics company, which further solidified its position in the market.

The main products and services offered by RBM include its comprehensive panel of multiplex immunoassays, which enable the simultaneous measurement of multiple biomarkers in a single sample. These assays are used in various research areas, including drug discovery and development, clinical diagnostics, and personalized medicine. On a global scale, RBM has established partnerships with numerous pharmaceutical and biotechnology companies, academic institutions, and research organizations.

These collaborations enable the company to expand its reach and provide its services to a wide range of clients and research initiatives. In terms of market position, RBM has a strong foothold in the biomarker testing industry. Its comprehensive panel of multiplex immunoassays sets it apart from competitors, allowing for efficient and cost-effective analysis of biomarkers.

The company's reputation for providing accurate and reliable results has contributed to its success and growth in the market. In recent years, RBM has undergone several significant changes. Its acquisition by Myriad Genetics has brought new resources and opportunities for expansion.

The company has also continued to innovate and develop new assays, further solidifying its position as a leader in the field. As of the latest available information, RBM continues to operate under the Myriad Genetics brand. It remains committed to advancing biomarker testing and analysis, and it continues to provide its comprehensive panel of multiplex immunoassays to clients worldwide.

The company's dedication to excellence and its strong market position position it as a key player in the field of biomarker testing